• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

EPHA2 Gene Record

  • Summary
  • Interactions
  • Claims
  • EPHA2 1969 Druggable Genome

    Alternate Names:

    1969
    EPH RECEPTOR A2
    EPHA2
    ARCC2
    CTPA
    CTPP1
    CTRCT6
    ECK
    176946
    3386
    ENSG00000142627
    OTTHUMG00000009527
    P29317
    EPHA2_HUMAN
    EPHRIN TYPE-A RECEPTOR 2 PRECURSOR (EC 2.7.1.112) (TYROSINE-PROTEIN KINASE RECEPTOR ECK) (EPITHELIAL CELL KINASE). [SOURCE:UNIPROT/SWISSPROT;ACC:P29317]
    Tyrosine-protein kinase receptor ECK
    Epithelial cell kinase
    Ephrin type-A receptor 2
    T57278

    Gene Info:

    Target Subclass Kinase
    Target Subclass Eph
    Transmembrane Helix Count 1
    Target Main Class Receptors
    Human Readable Name DRUGGABLE GENOME
    Interpro Short Name Ser-Thr/Tyr_kinase_cat_dom
    Human Readable Name KINASE
    Interpro Acc IPR001245
    Interpro Type Domain
    Uniprot Status Swiss-Prot
    Uniprot Evidence 1: Evidence at protein level
    Interpro Name Serine-threonine/tyrosine-protein kinase catalytic domain
    Target Class Receptors
    Target Subclass EC:2.7.10.1
    Gene Biotype PROTEIN_CODING
    (12 More Sources)

    Gene Categories: Category Details

    CELL SURFACE
    KINASE
    TYROSINE KINASE
    DRUGGABLE GENOME

    Publications:

    Faoro et al., 2010, EphA2 mutation in lung squamous cell carcinoma promotes increased cell survival, cell invasion, focal adhesions, and mammalian target of rapamycin activation., J. Biol. Chem.
    Lindauer et al., 2010, Dasatinib., Recent Results Cancer Res.
    Imming et al., 2006, Drugs, their targets and the nature and number of drug targets., Nat Rev Drug Discov
    Overington et al., 2006, How many drug targets are there?, Nat Rev Drug Discov
    Konecny et al., 2009, Activity of the multikinase inhibitor dasatinib against ovarian cancer cells., Br. J. Cancer
    Buettner et al., 2008, Inhibition of Src family kinases with dasatinib blocks migration and invasion of human melanoma cells., Mol. Cancer Res.
    Wang et al., 2007, Identification of candidate predictive and surrogate molecular markers for dasatinib in prostate cancer: rationale for patient selection and efficacy monitoring., Genome Biol.
    Incerti M et al., 2013, Amino acid conjugates of lithocholic acid as antagonists of the EphA2 receptor., J Med Chem
  • LITHOGLYCOCHOLATE   EPHA2

    Interaction Score: 7.27

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    23489211


    Sources:
    DTC

  • DASATINIB   EPHA2

    Interaction Score: 0.68

    Interaction Types & Directionality:
    antagonist (inhibitory)
    inhibitor (inhibitory)

    Interaction Info:
    Clinical Status preclinical
    Pathway activation
    Variant Effect gain-of-function

    PMIDs:
    20360610 20072833 17016423 17139284 19861960 19010823 18047674


    Sources:
    DTC TdgClinicalTrial ChemblInteractions TEND DoCM MyCancerGenomeClinicalTrial

  • CHEMBL578061   EPHA2

    Interaction Score: 0.15

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • MLN-8054   EPHA2

    Interaction Score: 0.13

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • REGORAFENIB   EPHA2

    Interaction Score: 0.13

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:

    PMIDs:
    None found


    Sources:
    MyCancerGenomeClinicalTrial

  • SNS-314   EPHA2

    Interaction Score: 0.09

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • ALISERTIB   EPHA2

    Interaction Score: 0.09

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • OSI-632   EPHA2

    Interaction Score: 0.08

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • VANDETANIB   EPHA2

    Interaction Score: 0.07

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Ephrin receptor inhibitor
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • LINIFANIB   EPHA2

    Interaction Score: 0.05

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • TOZASERTIB   EPHA2

    Interaction Score: 0.05

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • R-406   EPHA2

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • SORAFENIB   EPHA2

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • RG-1530   EPHA2

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • CYC-116   EPHA2

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • ILORASERTIB   EPHA2

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • PF-00562271   EPHA2

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • Ensembl: ENSG00000142627

    • Version: 101_38

    Alternate Names:
    EPHA2 Ensembl Gene Name

    Gene Info:
    Gene Biotype PROTEIN_CODING

    Publications:

  • TEND: P29317

    • Version: 01-August-2011

    Alternate Names:
    ENSG00000142627 Ensembl Gene Id
    1969 Entrez Gene Id
    P29317 Uniprot Accession

    Gene Info:
    Target Subclass Kinase
    Target Subclass Eph
    Transmembrane Helix Count 1

    Publications:

  • TdgClinicalTrial: P29317

    • Version: January-2014

    Alternate Names:
    EPHA2 Gene Symbol

    Gene Info:
    Target Class Receptors
    Target Subclass EC:2.7.10.1

    Publications:

  • RussLampel: ENSG00000142627

    • Version: 26-July-2011

    Alternate Names:
    ENSG00000142627 Ensembl Gene Id
    EPHA2 Display Id
    EPHRIN TYPE-A RECEPTOR 2 PRECURSOR (EC 2.7.1.112) (TYROSINE-PROTEIN KINASE RECEPTOR ECK) (EPITHELIAL CELL KINASE). [SOURCE:UNIPROT/SWISSPROT;ACC:P29317] Description

    Gene Info:
    Human Readable Name DRUGGABLE GENOME

    Gene Categories:
    DRUGGABLE GENOME

    Publications:

  • HopkinsGroom: P29317

    • Version: 11-September-2012

    Alternate Names:
    EPHRIN TYPE-A RECEPTOR 2 Uniprot Protein Name
    EPHA2 Uniprot Gene Name
    ENSG00000142627 Ensembl Gene Id

    Gene Info:
    Interpro Short Name Ser-Thr/Tyr_kinase_cat_dom
    Human Readable Name DRUGGABLE GENOME
    Human Readable Name KINASE

    Gene Categories:
    KINASE, DRUGGABLE GENOME

    Publications:

  • DoCM: EPHA2

    • Version: 27-September-2017

    Alternate Names:

    Gene Info:

    Publications:
    Faoro et al., 2010, EphA2 mutation in lung squamous cell carcinoma promotes increased cell survival, cell invasion, focal adhesions, and mammalian target of rapamycin activation., J. Biol. Chem.

  • DTC: EPHA2

    • Version: 02-September-2020

    Alternate Names:

    Gene Info:

    Publications:
    Incerti M et al., 2013, Amino acid conjugates of lithocholic acid as antagonists of the EphA2 receptor., J Med Chem

  • HingoraniCasas: ENSG00000142627

    • Version: 31-May-2017

    Alternate Names:
    ENSG00000142627 Gene Symbol
    EPHA2 Ensembl Id

    Gene Info:

    Gene Categories:
    DRUGGABLE GENOME

    Publications:

  • ChemblInteractions: ECK

    • Version: chembl_23

    Alternate Names:
    ECK GENE_SYMBOL
    EPHA2 GENE_SYMBOL
    Ephrin type-A receptor 2 UNIPROT

    Gene Info:

    Publications:

  • GO: EPHA2

    • Version: 01-February-2022

    Alternate Names:
    ECK GO Gene Synonym

    Gene Info:

    Gene Categories:
    CELL SURFACE

    Publications:

  • Tempus: EPHA2

    • Version: 11-November-2018

    Alternate Names:
    EPHA2 Gene Symbol

    Gene Info:

    Gene Categories:
    CLINICALLY ACTIONABLE

    Publications:

  • dGene: EPHA2

    • Version: 27-Jun-2013

    Alternate Names:
    1969 Gene ID
    ARCC2 dGene Synonym
    CTPA dGene Synonym

    Gene Info:

    Gene Categories:
    KINASE, TYROSINE KINASE

    Publications:

  • TTD: Ephrin type-A receptor 2

    • Version: 2020.06.01

    Alternate Names:
    EPHA2 TTD Gene Abbreviation
    T57278 TTD Target ID

    Gene Info:

    Publications:

  • Pharos: EPHA2

    • Version: 01-February-2022

    Alternate Names:
    Ephrin type-A receptor 2 Gene Name
    P29317 UniProt ID

    Gene Info:

    Gene Categories:
    KINASE

    Publications:

  • ClearityFoundationClinicalTrial: EPHA2

    • Version: 15-June-2013

    Alternate Names:

    Gene Info:

    Publications:

  • MyCancerGenomeClinicalTrial: EPHA2

    • Version: 30-February-2014

    Alternate Names:

    Gene Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21